Leana Mahmoud1, Andrew R Zullo2, Caitlyn Blake3, Xing Dai4, Bradford B Thompson5, Linda C Wendell6, Karen L Furie4, Michael E Reznik5, Ali Mahta7. 1. Department of Pharmacy, Rhode Island Hospital, Providence, Rhode Island, USA. 2. Department of Pharmacy, Rhode Island Hospital, Providence, Rhode Island, USA; Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA. 3. Department of Pharmacy, Rhode Island Hospital, Providence, Rhode Island, USA; University of Rhode Island College of Pharmacy, Kingston, Rhode Island, USA. 4. Department of Neurology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. 5. Department of Neurology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Department of Neurosurgery, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. 6. Department of Neurology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Department of Neurosurgery, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Section of Medical Education, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. 7. Department of Neurology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Department of Neurosurgery, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. Electronic address: ali_mahta@brown.edu.
Abstract
BACKGROUND: Nimodipine improves outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). However, the impact of alternative dosing strategies on outcome remains unclear. METHODS: We performed a retrospective cohort study of consecutive patients admitted with aSAH to an academic referral center from 2016 to 2019. Patients with a confirmed aneurysm cause who received nimodipine were included; patients who died or had withdrawal of life-sustaining treatment within 24 hours of admission were excluded. Univariable and multivariable modified Poisson regression models were used to identify predictors of using modified nimodipine dosing (30 mg every 2 hours) versus standard dosing (60 mg every 4 hours). Inverse probability weighted and modified Poisson regression models were used to estimate adjusted risk ratios (RRs) for outcome measures, with poor outcome defined as modified Rankin Scale score 4-6 at 3 months. RESULTS: We identified 175 patients with aSAH who met eligibility criteria (mean [SD] age = 57 [13.2] years, 62% female, 73% White); 49% (n = 86) received modified nimodipine dosing. A modified dose was used more frequently in women (RR 2.08, 95% confidence interval [CI] 1.11-3.89, P = 0.02), patients with vasospasm (RR 3.47, 95% CI 1.84-6.51, P < 0.001), and patients who required vasopressors (RR 1.73, 95% CI 1.3-2.32, P < 0.001). Modified dosing was not associated with poor functional outcome (inverse probability weighted RR 1.1, 95% CI 0.8-1.4, P = 0.65). CONCLUSIONS: Modified dosing of nimodipine is well tolerated and may not be associated with worse functional outcome. Prospective studies are needed to better assess the relationship between nimodipine dosing and outcomes in patients with aSAH.
BACKGROUND: Nimodipine improves outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). However, the impact of alternative dosing strategies on outcome remains unclear. METHODS: We performed a retrospective cohort study of consecutive patients admitted with aSAH to an academic referral center from 2016 to 2019. Patients with a confirmed aneurysm cause who received nimodipine were included; patients who died or had withdrawal of life-sustaining treatment within 24 hours of admission were excluded. Univariable and multivariable modified Poisson regression models were used to identify predictors of using modified nimodipine dosing (30 mg every 2 hours) versus standard dosing (60 mg every 4 hours). Inverse probability weighted and modified Poisson regression models were used to estimate adjusted risk ratios (RRs) for outcome measures, with poor outcome defined as modified Rankin Scale score 4-6 at 3 months. RESULTS: We identified 175 patients with aSAH who met eligibility criteria (mean [SD] age = 57 [13.2] years, 62% female, 73% White); 49% (n = 86) received modified nimodipine dosing. A modified dose was used more frequently in women (RR 2.08, 95% confidence interval [CI] 1.11-3.89, P = 0.02), patients with vasospasm (RR 3.47, 95% CI 1.84-6.51, P < 0.001), and patients who required vasopressors (RR 1.73, 95% CI 1.3-2.32, P < 0.001). Modified dosing was not associated with poor functional outcome (inverse probability weighted RR 1.1, 95% CI 0.8-1.4, P = 0.65). CONCLUSIONS: Modified dosing of nimodipine is well tolerated and may not be associated with worse functional outcome. Prospective studies are needed to better assess the relationship between nimodipine dosing and outcomes in patients with aSAH.
Authors: Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda Journal: J Biomed Inform Date: 2019-05-09 Impact factor: 6.317
Authors: J D Pickard; G D Murray; R Illingworth; M D Shaw; G M Teasdale; P M Foy; P R Humphrey; D A Lang; R Nelson; P Richards Journal: BMJ Date: 1989-03-11
Authors: G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou Journal: N Engl J Med Date: 1983-03-17 Impact factor: 91.245
Authors: S M Dorhout Mees; G J E Rinkel; V L Feigin; A Algra; W M van den Bergh; M Vermeulen; J van Gijn Journal: Cochrane Database Syst Rev Date: 2007-07-18
Authors: Corinne Fischer; Johannes Goldberg; Sonja Vulcu; Franca Wagner; Daniel Schöni; Nicole Söll; Matthias Hänggi; Jörg Schefold; Christian Fung; Jürgen Beck; Andreas Raabe; Werner J Z'Graggen Journal: Front Neurol Date: 2019-10-31 Impact factor: 4.003